GlassScriptPhysician profile
Morris Wisniewski
NPI 1639112246
$2,797.56
in general payments reported to CMS, 2019-2025
22 companies · $503 in 2025
The $503 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $935 · 2020: $210 · 2023: $539 · 2024: $611 · 2025: $503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,653.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,653.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $509.30 | 2019-2025 | Evenity, Repatha, Prolia |
| Glaxosmithkline, LLC. | $334.45 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $312.83 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $229.62 | 2019-2020 | |
| Pfizer INC. | $184.71 | 2019-2025 | |
| Lilly USA, LLC | $180.51 | 2019-2024 | Mounjaro |
| Stryker Corporation | $165.27 | 2023 | Clarifix Cryotherapy Device |
| Bayer Healthcare Pharmaceuticals INC. | $163.02 | 2024 | |
| Novartis Pharmaceuticals Corporation | $124.15 | 2019-2023 | |
| Genzyme Corporation | $91.98 | 2024 | |
| Exact Sciences Corporation | $81.26 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $78.83 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $72.98 | 2023-2024 | Rexulti |
| Merck Sharp & Dohme LLC | $62.32 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.05 | 2020-2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $32.16 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $27.66 | 2019 | |
| Boston Scientific Corporation | $23.21 | 2023 | |
| Si-Bone, INC. | $18.26 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $16.09 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.46 | 2020 | |
| Idorsia Pharmaceuticals US INC | $13.44 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morris Wisniewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.